Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CHEO Genetics Diagnostic Laboratory, |
RCV001170469 | SCV001333049 | uncertain significance | Cardiomyopathy | 2018-10-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001873572 | SCV002285163 | uncertain significance | Dilated cardiomyopathy 1AA; Primary familial hypertrophic cardiomyopathy | 2023-07-28 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 425 of the ACTN2 protein (p.Leu425Pro). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ACTN2 protein function. ClinVar contains an entry for this variant (Variation ID: 915594). This variant has not been reported in the literature in individuals affected with ACTN2-related conditions. This variant is not present in population databases (gnomAD no frequency). |
Fulgent Genetics, |
RCV002480583 | SCV002792615 | uncertain significance | Dilated cardiomyopathy 1AA; Myopathy, congenital, with structured cores and z-line abnormalities; Myopathy, distal, 6, adult-onset, autosomal dominant | 2021-09-12 | criteria provided, single submitter | clinical testing |